International Clinical Psychopharmacology最新文献_第2页

Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis. 西班牙语版本和一系列评定量表和视觉模拟量表的验证，以评估大麻的主观影响。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2023-11-20 DOI: 10.1097/YIC.0000000000000498

Alberto Sainz-Cort, Marta Martín-Islas, Genís Oña, Daniel Jimenez-Garrido, Miriam López-Navarro, Elena Muñoz-Marron, Raquel Viejo-Sobera, Jose Carlos Bouso

{"title":"Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis.","authors":"Alberto Sainz-Cort, Marta Martín-Islas, Genís Oña, Daniel Jimenez-Garrido, Miriam López-Navarro, Elena Muñoz-Marron, Raquel Viejo-Sobera, Jose Carlos Bouso","doi":"10.1097/YIC.0000000000000498","DOIUrl":"10.1097/YIC.0000000000000498","url":null,"abstract":"Cannabis is being legalized for medical and recreational purposes all around the world. However, the understanding of the psychological effects of cannabis is still limited, and it has been previously linked to mental disorders such as schizophrenia. Lately, new scales have been created and adapted to measure its psychological effects. The aim of this study is to create Spanish versions of some of these scales and test their psychometric characteristics. One hundred sixteen participants were recruited from Cannabis Social Clubs (CSC) in Barcelona, Spain. Participants under the effects of their own cannabis completed the Cannabis Experience Questionnaire-modified version (CEQ-mv), Addiction Research Centre Inventory-18 (ARCI-18), Psychotomimetic States Inventory (PSI) and Visual Analogue Scales (VAS). Questionnaires were completed in the CSC, providing a naturalistic setting for the study. Exploratory factor analysis and internal consistency were analyzed. PSI was reduced from a 6-factor to a 4-factor model with adequate to low reliability, ARCI-18 was reduced from a 3-factor to a 2-factor model with good reliability, and VAS were reduced from a 4-factor to a 3-factor model, also with good reliability. These questionnaires showed adequate reliability and can be used in future studies to test the subjective effects of cannabis in clinical and naturalistic settings.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"91-99"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of the Spanish version of the multifaceted empathy test: comparison between cannabis use effects and controls in social cognition. 西班牙文版多方面移情测试的验证：使用大麻影响与社会认知对照组的比较。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-06-28 DOI: 10.1097/YIC.0000000000000544

Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jimenez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz-Marron, Luis Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens, José Carlos Bouso

{"title":"Validation of the Spanish version of the multifaceted empathy test: comparison between cannabis use effects and controls in social cognition.","authors":"Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jimenez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz-Marron, Luis Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens, José Carlos Bouso","doi":"10.1097/YIC.0000000000000544","DOIUrl":"10.1097/YIC.0000000000000544","url":null,"abstract":"Objective: While social cognition is shown to be impaired in several mental disorders, the effects of cannabis on social cognition are still not clear. Past studies have used the multifaceted empathy test (MET) to study social cognition. This study aims to test the validity of the MET Spanish version and to evaluate the effects of cannabis use on social cognition.Methods: In total 116 participants from a Cannabis Social Club (CSC) completed the MET and the reading the mind in the eyes test (RMET) under the effects of cannabis and were compared to 86 university students (control group). Internal consistency and convergent validity were assessed. Cognitive empathy (CE) and emotional empathy (EE) were tested in both groups.Results: The MET CE scale shows low internal consistency, while the EE scale shows high internal consistency. Items showed similar difficulty for both groups. Cannabis users showed deficient overall emotional recognition, with reduced scores associated with positive stimuli. Overall scores for EE were similar for both groups, but the experimental group scored lower with negative stimuli when compared to controls.Conclusion: This study validates the MET Spanish version for its use in future studies. Results confirmed deficient emotional recognition in cannabis users and a dampened reaction to negative stimuli for the first time.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"100-109"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding treatment domains across psychiatric disorders.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2025-01-29 DOI: 10.1097/YIC.0000000000000581

Alessandro Serretti

引用次数: 0

Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients. 阿戈美拉汀治疗成人广泛性焦虑症的系统综述和网络荟萃分析。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-05-20 DOI: 10.1097/YIC.0000000000000551

Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf, Elzbieta Olewinska, Paulina Pierzchala, Marwa Mezghani, Mateusz Nikodem, Pierre Lévy

{"title":"Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients.","authors":"Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf, Elzbieta Olewinska, Paulina Pierzchala, Marwa Mezghani, Mateusz Nikodem, Pierre Lévy","doi":"10.1097/YIC.0000000000000551","DOIUrl":"10.1097/YIC.0000000000000551","url":null,"abstract":"This systematic literature review aimed to assess the efficacy and tolerability of agomelatine versus approved medications for the treatment of generalized anxiety disorder (GAD) in adult patients. We selected randomized controlled trials on various medications used to treat GAD in adult patients. An existing systematic literature review ( Kong et al ., 2020 ) was used to identify relevant studies published before 2020. Outcomes of remission and discontinuation due to adverse events (AEs) were analyzed, following a random-effects network meta-analysis approach. Of 25 identified studies, 20 and 22 studies were included in the network meta-analysis for studying the remission and discontinuation (due to AEs) outcomes, respectively. A statistically significant difference in the remission rate was observed between agomelatine and pregabalin [odds ratio (OR), 2.22; 95% confidence interval (CI), 1.19-4.21]. For the other comparators, the results were nonsignificant; however, all the point estimates were in favor of agomelatine. Similarly, for discontinuation because of AEs, the point estimates leaned consistently toward agomelatine suggesting its higher tolerability. The probabilities of agomelatine having the highest remission rate and lowest discontinuation (due to AEs) rate were 67% and 68%, respectively. Based on its demonstrated effectiveness and tolerability, agomelatine can be considered as a drug of choice for the treatment of GAD.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"62-74"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Pilates effective in improving depressive disorders? A comprehensive overview. 普拉提能有效改善抑郁障碍吗？全面概述。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-02-29 DOI: 10.1097/YIC.0000000000000541

Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli

{"title":"Is Pilates effective in improving depressive disorders? A comprehensive overview.","authors":"Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000541","DOIUrl":"10.1097/YIC.0000000000000541","url":null,"abstract":"Depressive disorders are disabling conditions that account for high social costs. Pilates demonstrated to have several beneficial effects on health. Objective of this manuscript was to systematically review the literature about the effects of Pilates on depressive disorders. A bibliographic search was conducted in the main database sources (Pubmed, Medline, and Scopus). The inclusion criteria consisted of articles written in English language about the effectiveness of Pilates on depressive symptoms. Most of included studies are randomized controlled trials (10 out of 12). The available literature agrees in indicating that Pilates is effective in improving depressive symptoms especially when compared to inactivity and when this practice is administered for a medium-long period (8-16 weeks). In addition, Pilates seems to have at least comparable effectiveness than aerobic exercise. Pilates can be considered a reliable complementary treatment for people with depressive disorders. These findings should be interpreted considering the different types of practice administered as well as the different duration of the programs or rating scales used to assess mood symptoms. Studies with a more homogenous design are needed to confirm and make generalizable the results presented in this review.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"53-61"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Points regarding neuroscience-based nomenclature: evaluating its impact on psychiatric residency training.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2025-01-29 DOI: 10.1097/YIC.0000000000000561

Jeroen De Troij, Chris Bervoets

引用次数: 0

The potential use of daridorexant in eating disorders: beyond the treatment of insomnia? 达立酮在饮食失调症中的潜在用途：超越失眠治疗？

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-05-10 DOI: 10.1097/YIC.0000000000000552

Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli

{"title":"The potential use of daridorexant in eating disorders: beyond the treatment of insomnia?","authors":"Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000552","DOIUrl":"10.1097/YIC.0000000000000552","url":null,"abstract":"A strong interplay exists between sleep and dietary habits, and sleep disturbances have been repeatedly documented in individuals with eating disorders (EDs). The orexin system - implicated in sleep regulation, energy homeostasis, and food reward - may represent a mechanist link between sleep alterations and disordered eating behaviors. Daridorexant is a dual orexin receptor antagonist (DORA) recently approved for the treatment of insomnia, with demonstrated efficacy and tolerability. Owing to its action on orexin neurons, the compound represents an intriguing option for addressing both sleep-related and core symptoms of EDs. By inhibiting motor hyperactivity, daridorexant may reduce excessive physical exercise in individuals with anorexia nervosa (AN) restricting type. Additionally, the compound may exert anti-binge effects, suggesting broad applicability in binge ED, bulimia nervosa, and binge/purging AN. In this framework, daridorexant emerges as a promising therapeutic option, offering a multifaceted approach to improving circadian rhythms, energy balance, and overall quality of life in individuals with diverse ED subtypes.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"115-118"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective serotonin reuptake inhibitors and quality of life: a meta-analysis of randomized placebo-controlled trials.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-02-28 DOI: 10.1097/YIC.0000000000000585

Dimy Fluyau, Vasanth Kattalai Kailasam, Paul Kim, Neelambika Revadigar

{"title":"Selective serotonin reuptake inhibitors and quality of life: a meta-analysis of randomized placebo-controlled trials.","authors":"Dimy Fluyau, Vasanth Kattalai Kailasam, Paul Kim, Neelambika Revadigar","doi":"10.1097/YIC.0000000000000585","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000585","url":null,"abstract":"The benefit of selective serotonin reuptake inhibitors (SSRIs) in improving quality of life (QoL) has been investigated in randomized-controlled trials (RCTs) with equivocal results. This study explored whether SSRIs could improve QoL in individuals with medical, psychiatric, and neuropsychiatric conditions. RCTs were searched in PubMed, Embase, Scopus, Ovid, and Google Scholar. Data were synthesized via a meta-analysis. Subgroup and meta-regression analyses were performed. The sample size was 9,070. Compared with placebo, SSRIs showed statistically significant improvements in QoL in cancer (d = 0.30), major depressive disorder (d = 0.27), premenstrual dysphoric disorder (d = 0.38), type 2 diabetes mellitus (d = 0.48), persistent depressive disorder (d = 0.32), and menopausal symptoms (d = 0.40). Paroxetine exhibited the highest effect size. No significant improvements were noted in chronic obstructive pulmonary disease (d = 0.65, P = 0.09), congestive heart failure (d = 0.46, P = 0.27), and irritable bowel syndrome (d = 0.26, P = 0.127). The reduction in depressive symptoms improved QoL. Small-study effects, high attrition rates, and demographic imbalances are limiting factors to recommend SSRIs to improve QoL. Future research should focus on QoL domains and pharmacological properties of each SSRI.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immediate-release vs. prolonged-release lithium formulations in bipolar disorder: a 2-year comparative study.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-02-19 DOI: 10.1097/YIC.0000000000000584

Margherita Barbuti, Martina Moriconi, Daria Bartolini, Ugo De Rosa, Camilla Elefante, Elisa Schiavi, Giulio Perugi

{"title":"Immediate-release vs. prolonged-release lithium formulations in bipolar disorder: a 2-year comparative study.","authors":"Margherita Barbuti, Martina Moriconi, Daria Bartolini, Ugo De Rosa, Camilla Elefante, Elisa Schiavi, Giulio Perugi","doi":"10.1097/YIC.0000000000000584","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000584","url":null,"abstract":"The aim of this study is to evaluate the therapeutic outcomes, tolerability, and adherence to immediate-release (IR) and prolonged-release (PR) lithium formulations in patients with bipolar disorder (BD) over a 2-year follow-up. This naturalistic study included 143 BD patients who initiated IR (48%) or PR (52%) lithium treatment at the inpatient and outpatient services of the University Hospital of Pisa. During follow-up, data were collected on side effects, treatment adherence, blood lithium levels, and creatinine and thyroid stimulating hormone concentrations. Clinical efficacy and functioning were assessed using the Clinical Global Impressions for Bipolar Disorder and Functioning Assessment Short Test scales. Approximately 50% of patients completed the 2-year follow-up, with similar dropout rates between the two groups. Both groups showed significant clinical improvement with comparable efficacy. PR lithium, however, was associated with fewer side effects, particularly tremors and gastrointestinal issues, leading to better adherence. Additionally, PR lithium administration resulted in more stable blood lithium levels. Despite its limitations, including the observational design, potential confounders such as concomitant medications, and a high dropout rate, these findings suggest that PR lithium formulations provide similar clinical efficacy to IR formulations but offer superior tolerability. Therefore, PR lithium represents a favorable option for improving adherence, particularly in patients at risk of treatment discontinuation.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-02-06 DOI: 10.1097/YIC.0000000000000583

Luca Giacovelli, Eleonora Piccoli, Paola Landi, Matteo Vismara, Beatrice Benatti, Bernardo Dell'Osso

{"title":"Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study.","authors":"Luca Giacovelli, Eleonora Piccoli, Paola Landi, Matteo Vismara, Beatrice Benatti, Bernardo Dell'Osso","doi":"10.1097/YIC.0000000000000583","DOIUrl":"10.1097/YIC.0000000000000583","url":null,"abstract":"Obsessive-compulsive disorder (OCD) is a chronic illness associated with significant functional impairment. Monotherapy with serotonin reuptake inhibitors (SRIs) often leads to only partial improvement of symptoms. In such cases, a common, well established, treatment approach for most patients is the augmentation of SRI therapy with antipsychotic medications. Brexpiprazole is an atypical antipsychotic agent that acts as a partial agonist of 5-HT1A, D2, and D3 receptors. Purpose of this retrospective observational study was to evaluate the effectiveness and tolerability of brexpiprazole as augmentation to SRIs in patients with treatment-resistant OCD. This preliminary study included a sample of 10 patients diagnosed with treatment-resistant OCD who underwent a 12-week trial of augmentative brexpiprazole, starting at a dose of 1 mg/day, with dosage adjustments based on clinical judgment. Treatment response was assessed through changes in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score from baseline to the end of the 12-week observation period. Adverse events were systematically recorded. Significant improvement was observed after the 12-week period: at the endpoint, seven patients (70%) achieved a ≥25% reduction in Y-BOCS total score compared to baseline, with five of them (50% of the overall sample) showing a more robust clinical response (≥35% reduction). Mild adverse effects, such as sedation and weight gain, were reported by two participants (20% of the overall sample). These findings suggest that brexpiprazole may offer a promising effectiveness and tolerability profile in the management of treatment-resistant OCD.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0